Nyxoah Announces Change to Board of Directors

Rhea-AI Summary

Nyxoah announced the resignation of Raymond Cohen from its board of directors, effective October 18, 2022. This change occurs in a company focused on innovative solutions for treating Obstructive Sleep Apnea (OSA), highlighting the need for strong leadership amid ongoing product developments. The company’s Genio® system received CE Mark approval in 2019 and is currently undergoing the DREAM IDE pivotal study for FDA approval. This management shift may impact Nyxoah’s strategic direction as it continues to expand its market presence.

Positive

• Strengthened leadership opportunities following board change.
• Continued focus on innovative solutions for OSA.

Negative

• Potential concerns regarding continuity in the board's strategic vision.

Nyxoah Announces Change to Board of Directors

Mont-Saint-Guibert, Belgium – October 24, 2022, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that Raymond Cohen resigned as member of the board of directors of the Company effective October 18, 2022.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest. 

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Contacts:
Nyxoah
Loic Moreau, Chief Financial Officer
corporate@nyxoah.com
+32 473 33 19 80

Jeremy Feffer, VP IR and Corporate Communications
jeremy.feffer@nyxoah.com
+1 917 749 1494

 

Attachment

• ENGLISH_Nyxoah PR Change to Board FINAL

FAQ

What recent management change occurred at Nyxoah?

Raymond Cohen resigned from Nyxoah's board of directors effective October 18, 2022.

What is the significance of Raymond Cohen's resignation at Nyxoah?

His resignation may affect the company's strategic direction and leadership dynamics amidst ongoing developments in their OSA treatments.

How does the management change impact Nyxoah's business?

The resignation of a board member may create opportunities for new leadership perspectives but could also raise continuity concerns.

What is Nyxoah known for?

Nyxoah specializes in developing innovative solutions for Obstructive Sleep Apnea, including the Genio® system.